基于代谢组学评价血液生物标志物对中枢神经系统肿瘤的诊断价值

目的 分析中枢神经系统肿瘤代谢组学图谱,评价小分子代谢物作为中枢神经系统肿瘤生物标志物的诊断价值.方法 本研究纳入126例中枢神经系统肿瘤患者和86例健康对照人群.通过液相色谱质谱联用技术(LC-MS/MS)检测血液中氨基酸和酰基肉碱,分析中枢神经系统肿瘤代谢组学图谱.用ROC曲线对小分子代谢物进行诊断效能分析.结果 中枢神经系统肿瘤代谢谱与健康人群有明显区别,19个指标有显著差异.肿瘤患者血液C2水平显著低于健康人群.Arg,C8和C18:2对中枢神经系统原发性肿瘤具有辅助诊断价值,ROC曲线下面积分别为0.868、0.895和0.756,灵敏度分别为82.6%、88.0%和60.9%,特异性分别为77.5%、80.8%和78.3%.结论 血液中小分子代谢物,包括氨基酸和酰基肉碱可作为中枢神经系统肿瘤辅助诊断新的生物标志物.

The Diagnostic Values of Plasma Metabolomics on Central Nervous System Tumors

Objective We aim to analyze the metabolomics profile of central nervous system tumor, and to explore diagnostic values of metabolites molecules as noninvasive biomarkers for central nervous system tumors.Methods This study included 126 patients with central nervous system (CNS) tumors and 86 cases of healthy subjects as control.The liquid chromatography mass spectrometry (LC-MS/MS) was used to detect the concentrations of amino acids and acylcarnitine from the plasma samples.We compared the difference of the metabolic fingerprint between the central nervous system tumor proteins and healthy controls.ROC curves were used to analyze diagnosis efficiency of small molecule metabolites.Results The results showed that metabolic spectrums, including 19 metabolomic molecules, were clearly different between patients with CNS cancer and healthy people,.The concentrations of C2 were significantly lower in CNS cancer patients than that of healthy people.The indexes Arg, C8 and C18:2 have potential to be the new biomarkers for primary tumor of the central nervous system, with AUCs of 0.868, 0.895 and 0.895.The sensitivities were 82.6%, 88.0% and 60.9%, and the specificities were 77.5%, 80.8% and 78.3%, respectively.Conclusion The plasma small molecule metabolites, including amino acids and acylcarnitine, could be used as new biomarkers for auxiliary diagnosis.